

SEQUENCE LISTING

<110> Novagen Holding Corporation

5 <120> RECOMBINANT HUMAN EPO-FC FUSION PROTEINS WITH PROLONGED HALF-LIFE
AND ENHANCED ERYTHROPOIETIC ACTIVITY IN VIVO

<130> N240 0002

10 <150> US 11/340,661
<151> 2006-01-27

<160> 10

15 <170> PatentIn version 3.3

<210> 1
<211> 1200
<212> DNA

20 <213> Artificial

<220>
<223> DNA encoding rHuEPO-Fc fusion protein

25 <400> 1
gccccaccac gacctcatctg tgacagccga gtctctggaga ggtacctctt ggaggccaag 60
gaggccgaga atatcacgac gggctgtgct gaacactgca gcttgaatga gaatatcact 120
30 gtcccagaca ccaaagttaa tttctatgcc tgggaagagga tggaggtcgg gcagcaggcc 180
gtagaagtct ggcagggcct ggccctgctg tcggaagctg tcctgcgggg ccaggccctg 240
ttggtcaact cttcccagcc gtgggagccc ctgcagctgc atgtggataa agccgtcagt 300
35 ggccttcgca gctcaccac tctgcttcgg gctctgcgag ccagaagga agccatctcc 360
cctccagatg cggcctcagc tgctccactc cgaacaatca ctgctgacac tttccgcaaa 420
40 ctcttccgag tctactccaa tttctccgg ggaaagctga agctgtacac aggggagggc 480
tgcaggacag gggacagagt tgagccaaa tctggtgaca aaactagtag atgccaccg 540
tgcccagcac ctgaactcct ggggggaccg tcagtcttcc tcttcccccc aaaaccaag 600
45 gacaccctca tgatctcccg gaccctgag gtcacatgcg tgggtgtgga cgtgagccac 660
gaagaccctg aggtcaagtt caactggtac gtggacggcg tggaggtgca taatgccaag 720
50 acaaagccgc gggaggagca gtacaacagc acgtaccgtg tggtcagcgt cctcaccgtc 780
ctgcaccagg actggctgaa tggcaaggag tacaagtgca aggtctccaa caaagccctc 840
ccagccccc tgcagaaaac catctccaaa gccaaagggc agccccgaga accacagggtg 900
55 tacaccctgc cccatcccg ggatgagctg accaagaacc aggtcagcct gacctgcctg 960
gtcaaaggct tctatcccag cgacatcgcc gtggagtggg agagcaatgg gcagccggag 1020
60 aacaactaca agaccacgcc tcccgctgctg gactccgaag gccccttctt cctctacagc 1080

```

aagctcaccg tggacaagag caggtggcag caggggaacg tcttctcatg ctccgtgatg 1140
catgaggctc tgcacaacca ctacacgcag aagagcctct ccctgtctcc gggtaaataa 1200

5
<210> 2
<211> 399
<212> PRT
<213> Artificial

10
<220>
<223> amino acid sequence of rHuEPO-Fc fusion protein

<400> 2

15
Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu
1 5 10 15

20
Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His
20 25 30

25
Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe
35 40 45

30
Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp
50 55 60

35
Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu
65 70 75 80

40
Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp
85 90 95

45
Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu
100 105 110

50
Arg Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala
115 120 125

55
Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val
130 135 140

60
Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala
145 150 155 160

65
Cys Arg Thr Gly Asp Arg Val Glu Pro Lys Ser Gly Asp Lys Thr Ser
165 170 175

70
Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
180 185 190

```

5 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
 195 200 205
 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
 210 215 220
 10 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
 225 230 235 240
 15 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
 245 250 255
 20 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
 260 265 270
 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
 275 280 285
 25 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
 290 295 300
 30 Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
 305 310 315 320
 35 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
 325 330 335
 40 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
 340 345 350
 Asp Gly Pro Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
 355 360 365
 45 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
 370 375 380
 50 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 385 390 395
 55 <210> 3
 <211> 1281
 <212> DNA
 <213> Artificial
 60 <220>
 <223> DNA encoding rHuEPO-Fc fusion protein with 27 amino acid signal

peptide

<400> 3
5 atgggggtgc acgaatgtcc tgccctggctg tggcttctcc tgtccctgct gtcgctccct 60
ctgggcctcc cagtcctggg cgtccaccca cgcctcatct gtgacagccg agtcctggag 120
aggtacctct tggaggccaa ggaggccgag aatatcacga cgggctgtgc tgaacactgc 180
10 agcttgaatg agaatatcac tgtcccagac accaaagtta atttctatgc ctggaagagg 240
atggaggctg ggcagcaggc cgtagaagtc tggcagggcc tggccctgct gtcggaagct 300
gtcctgcggg gccaggccct gttgggtcaac tcttcccagc cgtgggagcc cctgcagctg 360
15 catgtggata aagccgtcag tggccttcgc agcctcacca ctctgcttcg ggctctgcga 420
gccagaagg aagccatctc cctccagat gcggcctcag ctgctccact ccgaacaatc 480
20 actgctgaca ctttccgcaa actcttcga gtctactcca atttcctccg gggaaagctg 540
aagctgtaca caggggaggc ctgcaggaca ggggacagag ttgagcccaa atctggtgac 600
aaaactagta catgcccacc gtgccagca cctgaactcc tggggggacc gtcagtcttc 660
25 ctcttcccc caaaacccaa ggacaccctc atgatctccc ggaccctga ggtcacatgc 720
gtggtggtgg acgtgagcca cgaagaccct gaggtcaagt tcaactggta cgtggacggc 780
30 gtggagggtg ataatgccaa gacaaagccg cgggaggagc agtacaacag cacgtaccgt 840
gtggtcagcg tcttcaccgt cctgcaccag gactggtgta atggcaagga gtacaagtgc 900
aaggtctcca acaaagccct cccagcccc atcgagaaaa ccatctccaa agccaaagg 960
35 cagccccgag aaccacaggt gtacaccctg ccccatccc gggatgagct gaccaagaac 1020
caggtcagcc tgacctgcct ggtcaaaggc ttctatccca gcgacatcgc cgtggagtgg 1080
40 gagagcaatg ggcagccgga gaacaactac aagaccagc ctcccgctg gactccgac 1140
ggccccctt tctctacag caagctcacc gtggacaaga gcaggtggca gcaggggaac 1200
gtcttctcat gctccgtgat gcatgaggct ctgcacaacc actacacgca gaagagcctc 1260
45 tccctgtctc cgggtaaata a 1281

<210> 4
50 <211> 426
<212> PRT
<213> Artificial

<220>
55 <223> amino acid sequence of rHuEPO-Fc fusion protein with 27 amino acid signal peptide

<400> 4
60 Met Gly Val His Glu Cys Pro Ala Trp Leu Trp Leu Leu Leu Ser Leu
1 5 10 15

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 260 265 270

5

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 275 280 285

10

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 290 295 300

15

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 305 310 315 320

20

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
 325 330 335

Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 340 345 350

25

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 355 360 365

30

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Pro Phe Phe
 370 375 380

35

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 385 390 395 400

40

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 405 410 415

45

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 420 425

<210> 5
 <211> 40
 <212> DNA
 <213> Artificial

50

<220>
 <223> oligonucleotide primer

<400> 5

55

ccggaattcg ccaccatggg ggtgcacgaa tgtcctgcct

40

60

<210> 6
 <211> 42
 <212> DNA
 <213> Artificial

<220>
 <223> oligonucleotide primer
 5 <400> 6
 ttttcctttt gcggccgctt atttaccogg agacagggag ag 42

 10 <210> 7
 <211> 45
 <212> DNA
 <213> Artificial

 15 <220>
 <223> oligonucleotide primer

 <400> 7
 aggcctgcag gacaggggac agagttgagc ccaaactctgg tgaca 45
 20
 <210> 8
 <211> 45
 <212> DNA
 <213> Artificial
 25
 <220>
 <223> oligonucleotide primer

 <400> 8
 30 tgtcaccaga tttgggctca actctgtccc ctgtcctgca ggcct 45

 <210> 9
 <211> 45
 35 <212> DNA
 <213> Artificial

 <220>
 <223> oligonucleotide primer
 40
 <400> 9
 aggcctgcag gacaggggac agagttgagc ccaaactcttg tgaca 45

 45 <210> 10
 <211> 45
 <212> DNA
 <213> Artificial

 50 <220>
 <223> oligonucleotide primer

 <400> 10
 55 tgtcacaaaga tttgggctca actctgtccc ctgtcctgca ggcct 45